Core Insights - Therma Bright Inc. has secured a strategic commercial order for an initial 100 Venowave™ units from Horizon Health, marking a significant step in its commercial scaling strategy [1][4] - The partnership with Horizon Health positions Venowave™ to capture a substantial share of the vascular recovery market in the U.S., leveraging Horizon's established network [3][4] Company Developments - The order follows a successful proof-of-concept phase in 2025, during which Therma Bright optimized its delivery and support protocols for the U.S. market [2] - Horizon Health, a leader in durable medical equipment, has a network that prescribes over 3,000 compression products monthly, enhancing the potential reach of Venowave™ [3][6] Market Expansion - Therma Bright is exploring opportunities to position Venowave™ for cosmetic applications in wellness and aesthetic healthcare clinics, indicating potential growth in the cosmetic wellness market [5] - Preliminary feedback suggests that Venowave™ could support lymphatic drainage and post-procedure recovery, expanding its application beyond clinical settings [5]

Financial Data and Key Metrics Changes - The company reported net revenue of $23.4 million for Q1 2025, representing a 26% year-over-year growth, driven primarily by a 28% increase in sales of soft tissue repair products to $20.5 million [5][6] - Gross profit increased by $5 million or 30% to $21.6 million, with gross margin rising approximately 240 basis points to 92% of net revenue [22] - The net loss for Q1 2025 was $3.5 million or $0.41 per diluted share, compared to a net loss of $1.8 million or $0.21 per diluted share in the previous year [24] Business Line Data and Key Metrics Changes - In the Synera Surgical segment, adjusted EBITDA increased by $1.5 million year-over-year to $2.7 million, while the net loss increased by $200,000 to $600,000 [6][24] - The Tissue Health Plus segment reported a net loss of $2.9 million, up from a net loss of $1.4 million in the previous year, with a segment adjusted EBITDA loss of $2 million compared to a loss of $900,000 last year [24] Market Data and Key Metrics Changes - The company expanded its distributor network to over 400 partners, up from over 250 in Q1 2024, enhancing sales coverage in key markets across the U.S. [10] - The number of healthcare facilities served increased to over 1,300, compared to over 1,080 facilities in the prior year [11] Company Strategy and Development Direction - The company is focused on enhancing its new product pipeline and has secured distribution rights to two additional technologies [7] - The strategy includes investing in the Tissue Health Plus segment and launching a pilot program with a wound care provider later in Q2 2025 [6][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth opportunities ahead, particularly in the Synera Surgical segment, and expects improvements in profitability for 2025 [27] - The company is actively seeking financial partners to support the execution of its Tissue Health Plus strategy [27] Other Important Information - The company amended the terms of its debt facility to provide increased financial flexibility [7] - As of March 31, 2025, the company had $20.7 million in cash and $42.8 million in principal debt obligations outstanding [25] Q&A Session Summary Question: Can you provide more details on your penetration rates and strategy for improving penetration at existing facilities? - The company employs a coupled approach between regional sales managers and distributor expansion to penetrate existing accounts deeper [31] Question: Are there any signals on reorder rates for your products? - The company has not provided specific reorder rates but noted that once surgeons gain comfort with their products, they tend to continue using them across more procedures [33] Question: How should we think about gross margin cadence through the remainder of 2025? - Management indicated that while there may not be significant further leverage on gross margins, consistency with past modeling is advisable [38] Question: What metrics will define success for the pilot program in Tissue Health Plus? - Success will be measured through clinician-facing metrics, operational metrics, and adoption metrics, including protocol adherence and clinician satisfaction [41][45]